Last Updated : May 17, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued Sort ascending |
|---|---|---|---|---|---|---|
| Jemperli | dostarlimab | Endometrial cancer | Active | |||
| Imbruvica | ibrutinib | Leukemia | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | ||
| Repatha | evolocumab | Primary hyperlipidemia | Active | |||
| Ultomiris | ravulizumab | Generalized Myasthenia Gravis | Pending | |||
| Orgovyx | relugolix | Advanced prostate cancer | Active | |||
| Epkinly | epcoritamab | Relapsed or refractory diffuse large B-cell lymphoma | Active | |||
| Elrexfio | elranatamab | Relapsed or refractory multiple myeloma | Active | |||
| Opdivo | nivolumab | Stage IIB or IIC melanoma, adjuvant | Active | |||
| TBC | talquetamab | Relapsed or refractory multiple myeloma | Active | |||
| Bimzelx | bimekizumab | Ankylosing spondylitis | Active |
Last Updated : May 17, 2024